Prof A Murray Brunt

Title: Consultant Clinical Oncologist
Phone: +44 (0)1782 672565 (sec)
Email: murray.brunt@uhns.nhs.uk
Location: Staffordshire Oncology Centre, University Hospitals of North Midlands, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, United Kingdom
Role: ISTM Research theme: Therapeutics
Contacting me: By e-mail please.
Dr Murray Brunt

Prof Murray Brunt is Chief investigator on the FAST-Forward £3.6m NIHR-HTA funded trial and two others and active on 8 national/international breast cancer trial management groups. For the majority of trials in which he has been involved, Prof Brunt has been the principal investigator for North Staffordshire and  involved in all local aspects from the initiation, set up, recruitment through to follow up until trial closure.

Prof Brunt initiated the first weekly clinical trial follow up clinic in the Guy Hilton Research Centre, which has been running since 2007.  He been a major collaborator on a total of over 60 national or international studies and has just been appointed the first NIHR-Cancer Research lead for the West Midlands in the new national research set-up.

ISTM Research theme: Therapeutics

Prof Brunt’s research is in breast cancer, haematological malignancies (predominantly lymphomas), and skin cancer. It is conducted primarily through breast cancer clinical trials, on three levels:
- trial development, management, and  publication of results.
- a principal investigator and recruiter to trials
- the practical application of clinical trials and patient interaction.

The areas of breast cancer trials in which Prof Brunt is involved directly relate to his practice as a clinical oncologist:
- radiotherapy,
- chemotherapy,
- hormone therapy,
- targeted biological therapy

 

Selected Publications

  • Pai K, Gilani S, Brunt M. 2017. Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting. Clinical Oncology, vol. 29(6), e102-e103. doi> link>
  • Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM, Grp F-FTM. 2016. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. RADIOTHERAPY AND ONCOLOGY, vol. 120(1), 114-118. link> doi> link>
  • Coles C, Agrawal R, Ah-See ML, Algurafi H, Alhasso A, Brunt AM, Chan C, Griffin C, Harnett A, Hopwood P, Kirby A, Sawyer E, Syndikus I, Titley J, Tsang Y, Wheatley D, Wilcox M, Yarnold J, Bliss JM, TMG I. 2016. Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). EUROPEAN JOURNAL OF CANCER, vol. 57, S4. link> doi> link>
  • Brunt AM, Lupton S, Thorley K, Pearce L, Handley J. 2016. Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Rep Pract Oncol Radiother, vol. 21(3), 219-224. link> doi>
  • Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, Breast MIAMIMI. 2016. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. BREAST, vol. 26, 149-150. link> doi>

Full Publications List show

Journal Articles

  • Pai K, Gilani S, Brunt M. 2017. Bone Mineral Density Screening in Invasive Breast Cancer Patients Treated with Anastrozole in Adjuvant Setting. Clinical Oncology, vol. 29(6), e102-e103. doi> link>
  • Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM, Grp F-FTM. 2016. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. RADIOTHERAPY AND ONCOLOGY, vol. 120(1), 114-118. link> doi> link>
  • Coles C, Agrawal R, Ah-See ML, Algurafi H, Alhasso A, Brunt AM, Chan C, Griffin C, Harnett A, Hopwood P, Kirby A, Sawyer E, Syndikus I, Titley J, Tsang Y, Wheatley D, Wilcox M, Yarnold J, Bliss JM, TMG I. 2016. Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). EUROPEAN JOURNAL OF CANCER, vol. 57, S4. link> doi> link>
  • Brunt AM, Lupton S, Thorley K, Pearce L, Handley J. 2016. Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Rep Pract Oncol Radiother, vol. 21(3), 219-224. link> doi>
  • Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, Breast MIAMIMI. 2016. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. BREAST, vol. 26, 149-150. link> doi>
  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, Herceptin Adjuvant (HERA) Trial Study Team. 2013. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, vol. 382(9897), 1021-1028. link> doi>
  • Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im Y-H, Braybrooke JP, Brunt AM, Cheung K-L, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin H-J, Folkerd E, Dowsett M, Bliss JM, Investigators S. 2013. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. LANCET ONCOLOGY, vol. 14(10), 989-998. link> doi>
  • Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. 2013. Breast Radiotherapy: Less is More?. CLINICAL ONCOLOGY, vol. 25(2), 127-134. link> doi>
  • Earl HM, Hiller L, Dunn JA, Vallier A-L, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RCF, Twelves CJ, Cameron D, Bartlett JMS, Pharoah P, Provenzano E, Caldas C, Poole CJ. 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, vol. 107(8), 1257-1267. link> doi>
  • Yarnold JR, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, Bloomfield D, Bowen J, Brunt AM, Donovan E, Emson M, Goodman A, Harnett A, Haviland JS, Kaggwa R, Morden JP, Robinson A, Simmons S, Stewart A, Sydenham MA, Syndikus I, Tremlett J, Tsang Y, Wheatley D, Venables K, Grp FASTT. 2011. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). RADIOTHERAPY AND ONCOLOGY, vol. 100(1), 93-100. link> doi>
  • Murray N, Brunt M, Macbeth F, Winstanley J, Guideline Development Group. 2009. Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - a solid basis for good clinical practice. Clin Oncol (R Coll Radiol), vol. 21(5), 368-370. link> doi>
  • YARNOLD JR, BLISS JM, BRUNT M, EARL H, KAYE S, MASON M, MOSSMAN J, PERREN T, RICHARDS M. 1994. MANAGEMENT OF BREAST - REFER WOMEN TO MULTIDISCIPLINARY BREAST CLINICS. BRITISH MEDICAL JOURNAL, vol. 308(6930), 714-715. link> doi>

Other

  • Brunt AM, Sydenham M, Bliss J, Coles C, Gothard L, Harnett A, Haviland J, Syndikus I, Wheatley D, Yarnold J. 2009. A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015). EJC SUPPLEMENTS (vol. 7, p. 2). link>
  • Bloomfield D, Sydenham M, Le Vay J, Syndikus I, Hatton M, Bliss P, Dyson P, Kelly S, Agrawal R, Barrett-Lee P, Abson C, Owen JR, Kumar S, Brunt M, Whipp L, Illsley M, Bliss J, Yarnold J. 2004. Prospective randomised trial testing 5.7GY and 6.0GY fractions of whole breast radiotherapy in women with early breast cancer ('fast' trial). BRITISH JOURNAL OF CANCER (vol. 91, p. S80). link>
  • SuleSuso J, Scoble JE, Adab FA, Jones PW, Brunt AM. 1997. Hyperfractionated accelerated radiotherapy for carcinoma of the oesophagus. 5 years follow-up. EUROPEAN JOURNAL OF CANCER (vol. 33, p. 468). link>

Professional Memberships:
- Medical Defence Union
- Royal College of Radiologists
- Royal College of Physicians, London
- British Oncology Association
- Radiotherapists Visiting Society
- Hospital Consultant & Specialists Association
- North Staffordshire Medical Institute

Committee Memberships:
- National deputy lead for the Breast Site Orientated electronic Network (SOeN): 2006-present.
- Member of National Collaborating Centre for Cancer (NCCC) advanced breast cancer guideline development group: 2006-9 (the lifetime of the project).
- Member of West Midlands Cancer Intelligence Unit steering committee: 2005-present.
- Member of Regional peer review team from 1997, clinical team leader from 2005-present.
Chair of R & D steering committee: 2007 to present.
- Deputy Lead of NCRN R & D for North West Midlands Cancer Network 2004-6 (until networks amalgamated).